Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
1997 1
1998 3
1999 2
2000 1
2001 2
2002 2
2004 2
2005 1
2006 1
2007 2
2008 1
2010 1
2011 2
2013 1
2015 2
2016 4
2017 1
2020 2
2022 1
2023 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Management of radiation cystitis.
Smit SG, Heyns CF. Smit SG, et al. Nat Rev Urol. 2010 Apr;7(4):206-14. doi: 10.1038/nrurol.2010.23. Epub 2010 Mar 9. Nat Rev Urol. 2010. PMID: 20212517 Free article. Review.
Oral or parenteral agents that can be used to control hematuria include conjugated estrogens, pentosan polysulfate or WF10. Cystoscopy with laser fulguration or electrocoagulation of bleeding points is sometimes effective. ...
Oral or parenteral agents that can be used to control hematuria include conjugated estrogens, pentosan polysulfate or WF10. Cystoscop …
Hemorrhagic radiation cystitis.
Mendenhall WM, Henderson RH, Costa JA, Hoppe BS, Dagan R, Bryant CM, Nichols RC, Williams CR, Harris SE, Mendenhall NP. Mendenhall WM, et al. Am J Clin Oncol. 2015 Jun;38(3):331-6. doi: 10.1097/COC.0000000000000016. Am J Clin Oncol. 2015. PMID: 24322335 Review.
Various options are available and include oral agents (ie, sodium pentosan polysulfate), intravenous drugs (ie, WF10), topical agents (ie, formalin), hyperbaric oxygen, and endoscopic procedures (ie, electrical cautery, argon plasma coagulation, laser coagulation). ...
Various options are available and include oral agents (ie, sodium pentosan polysulfate), intravenous drugs (ie, WF10), topical agents …
WF10 stimulates NK cell cytotoxicity by increasing LFA-1-mediated adhesion to tumor cells.
Kühne L, Konstandin M, Samstag Y, Meuer S, Giese T, Watzl C. Kühne L, et al. J Biomed Biotechnol. 2011;2011:436587. doi: 10.1155/2011/436587. Epub 2011 May 3. J Biomed Biotechnol. 2011. PMID: 21629753 Free PMC article.
Animal studies suggest that WF10 enhances immunity against tumors. One possible explanation for such an effect is that WF10 stimulates natural killer cell cytotoxicity against malignant cells. ...These data demonstrate a direct effect of WF10 on the cytotoxic …
Animal studies suggest that WF10 enhances immunity against tumors. One possible explanation for such an effect is that WF10 st …
Interaction of the chlorite-based drug WF10 and chlorite with hemoglobin, methemoglobin and ferryl hemoglobin.
Pichert A, Arnhold J. Pichert A, et al. Arch Biochem Biophys. 2015 Nov 1;585:82-89. doi: 10.1016/j.abb.2015.09.009. Epub 2015 Sep 21. Arch Biochem Biophys. 2015. PMID: 26391926
The chlorite component of WF10 converts oxyhemoglobin into methemoglobin with a rate of 35.4 M(-1)s(-1). Methemoglobin is also formed upon the interaction of ferryl hemoglobin and WF10/chlorite. ...In all interconversions, the chlorite component of WF10 was t …
The chlorite component of WF10 converts oxyhemoglobin into methemoglobin with a rate of 35.4 M(-1)s(-1). Methemoglobin is also formed …
WF10 in xenotransplantation-a potential new approach.
Kemp E, Dieperink H, Horn T, Johansen A, Jensen J, Kemp G, Larsen S, Lillevang S, Svendsen M, Freilow E, Kuhlmann I, Kemp K. Kemp E, et al. Transplant Proc. 2000 Aug;32(5):1018-9. doi: 10.1016/s0041-1345(00)01092-7. Transplant Proc. 2000. PMID: 10936328 No abstract available.
Effect of WF10 (immunokine) on diabetic foot ulcer therapy: a double-blind, randomized, placebo-controlled trial.
Yingsakmongkol N, Maraprygsavan P, Sukosit P. Yingsakmongkol N, et al. J Foot Ankle Surg. 2011 Nov-Dec;50(6):635-40. doi: 10.1053/j.jfas.2011.05.006. Epub 2011 Jul 1. J Foot Ankle Surg. 2011. PMID: 21723750 Clinical Trial.
This randomized controlled trial was undertaken to evaluate the effect of WF10 (Immunokine) as an adjunct to the standard treatment of diabetic foot ulcer. A total of 40 participants were randomized into 2 groups of 20. ...The wound depth and wound area also decreased more …
This randomized controlled trial was undertaken to evaluate the effect of WF10 (Immunokine) as an adjunct to the standard treatment o …
Effect of WF10 (TCDO) on antigen presentation.
McGrath MS, Benike C, Kuehne FW, Engleman E. McGrath MS, et al. Transplant Proc. 1998 Dec;30(8):4200-4. doi: 10.1016/s0041-1345(98)01393-1. Transplant Proc. 1998. PMID: 9865348 No abstract available.
Development of WF10, a novel macrophage-regulating agent.
McGrath MS, Kahn JO, Herndier BG. McGrath MS, et al. Curr Opin Investig Drugs. 2002 Mar;3(3):365-73. Curr Opin Investig Drugs. 2002. PMID: 12054081
WF10 represents a new class of drug involved in regulating macrophage function both in vitro and in vivo. In the US, WF10 is being evaluated in patients with advanced HIV infection as an adjunct to highly active antiretroviral therapy (HAART). ...
WF10 represents a new class of drug involved in regulating macrophage function both in vitro and in vivo. In the US, WF10 is b …
The chlorite-based drug WF10 constantly reduces hemoglobin A1c values and improves glucose control in diabetes patients with severe foot syndrome.
Maraprygsavan P, Mongkolsuk J, Arnhold J, Kuehne FW. Maraprygsavan P, et al. J Clin Transl Endocrinol. 2016 May 5;4:53-58. doi: 10.1016/j.jcte.2016.05.001. eCollection 2016 Jun. J Clin Transl Endocrinol. 2016. PMID: 29159131 Free PMC article.
METHODS: Patients received five consecutive daily infusions of WF10. Three patients received a second cycle of WF10, and one patient a third cycle. RESULTS: On a group of twelve patients with diabetic foot syndrome, WF10 gradually reduced the HbA1c values fro …
METHODS: Patients received five consecutive daily infusions of WF10. Three patients received a second cycle of WF10, and one p …
Inhibition of the heme-induced hemolysis of red blood cells by thechlorite-based drug WF10.
Flemmig J, Schlorke D, Kühne FW, Arnhold J. Flemmig J, et al. Free Radic Res. 2016 Dec;50(12):1386-1395. doi: 10.1080/10715762.2016.1252838. Epub 2016 Nov 23. Free Radic Res. 2016. PMID: 27776433
Thus, inhibition of hemolysis by WF10 takes already place at those chlorite concentrations, where no degradation of the porphyrin ring occurs. As WF10 is applied in form of an intravenous infusion to patients with severe inflammatory states, these data support the h …
Thus, inhibition of hemolysis by WF10 takes already place at those chlorite concentrations, where no degradation of the porphyrin rin …
35 results